Evidence map›Paper›PMID 37631880›Full record

ArticleVaccines2023

Competing Heterogeneities in Vaccine Effectiveness Estimation.

Ariel Nikas, Hasan Ahmed, Veronika I Zarnitsyna

Abstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Ariel NikasDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Hasan AhmedDepartment of Biology, Emory University, Atlanta, GA 30322, USA.
Veronika I ZarnitsynaDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0003-3096-3695

Funding

Household Respiratory Virus SARS-CoV-2 Transmission and Immunity Sub-Study (HRTS)U01AI144616 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GORDON, AUBREE L, THOMAS, PAUL G. · 2019 to 2025
$43.7M
DYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSESU01AI150747 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, ANTIA, RUSTOM NOSHIR · 2020 to 2024
$5.9M
Multiscale modeling of influenza vaccination strategies for optimal T cell immunityU01HL139483 · NHLBI · EMORY UNIVERSITY · PI KOHLMEIER, JACOB E, ZARNITSYNA, VERONIKA I · 2018 to 2022
$3.5M
NHLBI NIH HHS U01 HL139483NIAID NIH HHS U01 AI144616NIAID NIH HHS U01 AI150747
6 · The paper itself

Abstract

Understanding the waning of vaccine-induced protection is important for both immunology and public health. Population heterogeneities in underlying (pre-vaccination) susceptibility and vaccine response can cause measured vaccine effectiveness (mVE) to change over time, even in the absence of pathogen evolution and any actual waning of immune responses. We use multi-scale agent-based models parameterized using epidemiological and immunological data, to investigate the effect of these heterogeneities on mVE as measured by the hazard ratio. Based on our previous work, we consider the waning of antibodies according to a power law and link it to protection in two ways: (1) motivated by correlates of risk data and (2) using a within-host model of stochastic viral extinction. The effect of the heterogeneities is given by concise and understandable formulas, one of which is essentially a generalization of Fisher's fundamental theorem of natural selection to include higher derivatives. Heterogeneity in underlying susceptibility accelerates apparent waning, whereas heterogeneity in vaccine response slows down apparent waning. Our models suggest that heterogeneity in underlying susceptibility is likely to dominate. However, heterogeneity in vaccine response offsets <10% to >100% (median of 29%) of this effect in our simulations. Our study suggests heterogeneity is more likely to 'bias' mVE downwards towards the faster waning of immunity but a subtle bias in the opposite direction is also plausible.

Indexed as

antibody waning by power lawfrailtyheterogeneityselectionsurvival analysisvaccine effectivenessvaccine efficacy

Identifiers

PMID37631880
PMCPMC10458793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.